Expedited drug review procedures final rule
Executive Summary
Due imminently based on FDA's projected regulatory agenda. In keeping with the agenda's usual optimism, FDA, in the Oct. 29 Federal Register, provided Oct. 31 as the date for publication of the final rule for expedited review of drugs for treating life-threatening/debilitating illnesses. The agenda also indicated that the interim final rule for retention of drug samples used in bioequivalence or bioavailability studies will issue in the near future. Final action is expected in May for an amendment to the IND regs that would include reasons for ceasing distribution of an experimental drug under a parallel track mechanism. According to the agenda, FDA expects to issue in March the final rule for food labeling regulations that will allow use of certain health messages.
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.